Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010–2015

References

• Mitsumoto HCD, Pioro EP. Amyotrophic lateral sclerosis. Philadelphia, PA: F.A. Davis Company; 1998.
   Google Scholar
• Charcot JMJ. A. Deux cas d’atrophie musculaire progressive avec lesions de la substance grise et des faisceaux antero-lateraux de la moelle epiniere [French]. Arch Physiol Neurol Pathol. 1869;2:744.
   Google Scholar
• Mehta P, Kaye W, Raymond J, Punjani R, Larson T, Cohen J. Prevalence of amyotrophic lateral sclerosis — United States, 2015. Morb Mortal Wkly Rep. 2018;67:1285–9. https://www.cdc.gov/mmwr/volumes/67/wr/pdfs/mm6746a1-H.pdf
   Google Scholar
• Wagner L, Rechtman L, Jordan H, Ritsick M, Sanchez M, Sorenson E, Kaye W. State and metropolitan area-based amyotrophic lateral sclerosis (ALS) surveillance. Amyotroph Lateral Scler Frontotemporal Degener. 2015;17:128–34.
   Google Scholar
• Ravits J, Appel S, Baloh RH, Barohn R, Brooks BR, Elman L, et al. Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology, and genetics are telling us about pathogenesis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:5–18.
   Google Scholar
• Boylan K. Familial amyotrophic lateral sclerosis. Neurol Clin. 2015;33:807–30.
   Google Scholar
• Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310–23.
   Google Scholar
• Ringel SP, Murphy JR, Alderson MK, Bryan W, England JD, Miller RG, et al. The natural history of amyotrophic lateral sclerosis. Neurology. 1993;43:1316–22.
   Google Scholar
• Chiò A, Calvo A, Mazzini L, Cantello R, Mora G, Moglia C, et al. Extensive genetics of ALS: a population-based study in Italy. Neurology. 2012;79:1983–9.
   Google Scholar
• Al-Chalabi A, Hardiman O, Kiernan MC, Chiò A, Rix-Brooks B, van den Berg LH. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 2016;15:1182–94.
   Google Scholar
• US Public Health Service. ALS registry act. 110th congress. Public law. Washington, DC: US Public Health Service, 2008:110–373. 122 Stat 4047. Available at: http://wwwn.cdc.gov/als/Download/ALS%20Registry%20Act%20.(Public%20Law%20110-373).pdf.
   Google Scholar
• Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors. J Neurol Sci. 1994;124:96–107.
   Google Scholar
• Antao VC, Horton DK. The national amyotrophic lateral sclerosis (ALS) registry. J Environ Health. 2012;75:28–30.
   Google Scholar
• Allen KD, Kasarskis EJ, Bedlack RS, Rozear MP, Morgenlander JC, Sabet A, et al. The national registry of veterans with amyotrophic lateral sclerosis. Neuroepidemiology. 2008;30:180–90. PMID: 18421218.
   Google Scholar
• Horton DK, Mehta P, Antao V. Quantifying a nonnotifiable disease in the United States: the national amyotrophic lateral sclerosis registry model. JAMA. 2014;312:1097–8.
   Google Scholar
• US Department of Health and Human Services. US department of health and human services regions. Washington, DC: US Department of Health and Human Services; 2017. Available at: https://www.hhs.gov/about/agencies/iea/regional-offices/index.html.
   Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169:13–21.
   Google Scholar
• Khishchenko N, Allen KD, Coffman CJ, Kasarskis EJ, Lindquist JH, Morgenlander JC, et al. Time to diagnosis in the national registry of veterans with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:125–32.
   Google Scholar
• Paganoni S, Macklin EA, Lee A, Murphy A,  Chang J, Zipf A, et al. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:453–6.
   Google Scholar
• Shook SJ, Pioro EP. Racing against the clock: recognizing, differentiating, diagnosing, and referring the amyotrophic lateral sclerosis patient. Ann Neurol. 2009;65:S10–S6.
   Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/riluzole study group. N Engl J Med. 1994;330:585–91.
   Google Scholar
• Abe K, Aoki M, Tsuji S, Itoyama Y, Sobue G, Togo M, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–12.
   Google Scholar
• Eisen A. How to improve the diagnostic process. J Neurol. 1999;246:III6–9.
   Google Scholar
• Galvin M, Gaffney R, Corr B, Mays I, Hardiman O. From first symptoms to diagnosis of amyotrophic lateral sclerosis: perspectives of an Irish informal caregiver cohort-a thematic analysis. BMJ Open. 2017;7:e014985.
   Google Scholar
• Logroscino G, Traynor BJ, Hardiman O, Chio A, Mitchell D, Swingler RJ, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81:385–90.
   Google Scholar
• Hardiman O, Al-Chalabi AA, Brayne C, Beghi E, van de Berg LH, Chio A, et al. The changing picture of amyotrophic lateral sclerosis: lessons from European registers. J Neurol Neurosurg Psychiatry. 2017;88:557–63.
   Google Scholar
• Stephens HE, Joyce NC, Oskarsson B. National study of muscle cramps in ALS in the USA. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:32–36.
   Google Scholar
• Caress JB, Ciarlone SL, Sullivan EA, Griffin LP, Cartwright MS. Natural history of muscle cramps in amyotrophic lateral sclerosis. Muscle Nerve. 2016;53:513–7.
   Google Scholar
• Wainger BJ, Kiskinis E, Mellin C, Wiskow O, Han SSW, Sandoe J, et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014;7:1–11.
   Google Scholar
• Turner MR, Brockington A, Scaber J, Hollinger H, Marsden R, Shaw PJ, et al. Pattern of spread and prognosis in lower limb-onset ALS. Amyotroph Lateral Scler. 2010;11:369–73.
   Google Scholar
• Fujimura-Kiyono C, Kimura F, Ishida S, Nakajima H, Hosokawa T, Sugino M, et al. Onset and spreading patterns of lower motor neuron involvements predict survival in sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2011;82:1244–9.
   Google Scholar
• Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med. 2010;38:S495–S501.
   Google Scholar
• Moglia C, Calvo A, Grassano M, Canosa A, Manera U, D’Ovidio F, et al. Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort. J Neurol Neurosurg Psychiatry. 2019;0:1–8.
   Google Scholar
• Piccione EA, Sletten DM, Staff NP, Low PA. Autonomic system and amyotrophic lateral sclerosis. Muscle Nerve. 2015;51:676–9.
   Google Scholar
• Moss AH, Casey P, Stocking CB, Roos RP, Brooks BR, Siegler M. Home ventilation for amyotrophic lateral sclerosis patients: outcomes, costs, and patient, family, and physician attitudes. Neurology. 1993;43:438–43.
   Google Scholar
• del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology. 2003;60:813–9.
   Google Scholar
• Traxinger K, Kelly C, Johnson BA, Lyles RH, Glass JD. Prognosis and epidemiology of amyotrophic lateral sclerosis: analysis of a clinic population, 1997–2011. Neurol Clin Pract. 2013;3:313–20.
   Google Scholar
• Chen L, Liu X, Tang L, Zhang N, Fan D. Long-term use of riluzole could improve the prognosis of sporadic amyotrophic lateral sclerosis patients: a real-world cohort study in China. Front Aging Neurosci. 2016;8:246.
   Google Scholar
• Mandrioli J, Malerba SA, Beghi E, Fini N, Fasano A, Zucchi E, et al. Riluzole and other prognostic factors in ALS: a population-based registry study in Italy. J Neurol. 2018; 265:817–27.
   Google Scholar
• Nygren I, Antonova K, Mattsson P, Askmark H. The ALS/MND prevalence in Sweden estimated by riluzole sales statistics. Acta Neurol Scand. 2005;111:180–4.
   Google Scholar
• Watanabe H, Atsuta N, Nakamura R, Hirakawa A, Watanabe H, Ito M, et al. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:230–6.
   Google Scholar
• Rooney JPK, Visser AE, D’Ovidio F, Vermeulen R, Beghi E, Chio A, et al. A case-control study of hormonal exposures as etiologic factors for ALS in women. Neurology. 2017;89:1283–90.
   Google Scholar
• US Census Bureau. Total population 2014 American community survey 1-year. Washington, DC: US Department of Commerce, US Census Bureau; 2014.
   Google Scholar
• Kaye WE, Wagner L, Wu R, Mehta P. Evaluating the completeness of the national ALS registry, United States. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:112–7.
   Google Scholar